Skip to main content
Equibles

ADAPY · Adaptimmune Therapeutics PLC · Investor Relations

Track ADAPY — free

Use ADAPY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADAPY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 +0.00 (+11.30%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2025

Substantial doubt about the company's ability to continue as a going concern.

“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”
View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B
Volume · Oct 20 80.26K Avg daily vol (3M) 144.54K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Key facts CIK 1621227 CUSIP 00653A107 Visit website Investor relations